See more : ArcelorMittal South Africa Ltd (ACL.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Revolution Medicines, Inc. Warrant (RVMDW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revolution Medicines, Inc. Warrant, a leading company in the Biotechnology industry within the Healthcare sector.
- Transcontinental Inc. (TCL-B.TO) Income Statement Analysis – Financial Results
- JBCC Holdings Inc. (9889.T) Income Statement Analysis – Financial Results
- Grupo Rotoplas S.A.B. de C.V. (AGUA.MX) Income Statement Analysis – Financial Results
- Bever Holding NV (BEVER.AS) Income Statement Analysis – Financial Results
- Sichuan Fulin Transportation Group Co., Ltd. (002357.SZ) Income Statement Analysis – Financial Results
Revolution Medicines, Inc. Warrant (RVMDW)
About Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.58M | 35.38M | 29.39M | 42.98M | 50.04M | 20.17M | 0.00 |
| Cost of Revenue | 0.00 | 9.66M | 7.33M | 132.25M | 91.76M | 1.76M | 1.19M |
| Gross Profit | 11.58M | 25.72M | 22.06M | -89.27M | -41.71M | 18.40M | -1.19M |
| Gross Profit Ratio | 100.00% | 72.71% | 75.05% | -207.68% | -83.36% | 91.25% | 0.00% |
| Research & Development | 423.14M | 253.07M | 186.95M | 132.25M | 91.76M | 51.08M | 26.59M |
| General & Administrative | 75.62M | 40.59M | 30.45M | 21.43M | 12.41M | 9.41M | 4.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.62M | 40.59M | 30.45M | 21.43M | 12.41M | 9.41M | 4.54M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.12M | 0.00 |
| Operating Expenses | 498.77M | 293.66M | 217.40M | 153.68M | 104.16M | 60.49M | 31.13M |
| Cost & Expenses | 498.77M | 293.66M | 217.40M | 153.68M | 104.16M | 60.49M | 31.13M |
| Interest Income | 47.48M | 9.15M | 929.00K | 2.24M | 2.19M | 777.00K | 105.00K |
| Interest Expense | 303.00K | 0.00 | 12.00K | 71.00K | 106.00K | 116.00K | 103.00K |
| Depreciation & Amortization | 9.31M | 9.66M | 7.33M | 6.55M | 3.34M | 1.76M | 1.19M |
| EBITDA | -430.58M | -239.47M | -179.75M | -101.91M | -48.59M | -39.91M | -29.84M |
| EBITDA Ratio | -3,718.32% | -704.14% | -636.54% | -252.33% | -97.10% | -197.91% | 0.00% |
| Operating Income | -487.19M | -258.28M | -188.01M | -110.70M | -54.12M | -40.33M | -31.13M |
| Operating Income Ratio | -4,207.12% | -730.01% | -639.70% | -257.54% | -108.15% | -200.00% | 0.00% |
| Total Other Income/Expenses | 47.29M | 9.15M | 917.00K | 2.17M | 2.08M | -1.46M | 2.00K |
| Income Before Tax | -439.89M | -249.13M | -187.09M | -108.53M | -52.04M | -41.79M | -31.13M |
| Income Before Tax Ratio | -3,798.71% | -704.14% | -636.58% | -252.50% | -103.99% | -207.24% | 0.00% |
| Income Tax Expense | -3.52M | -420.00K | -7.32M | -371.00K | -4.37M | -1.34M | 105.00K |
| Net Income | -436.37M | -248.71M | -179.77M | -108.16M | -47.66M | -41.79M | -31.13M |
| Net Income Ratio | -3,768.28% | -702.95% | -611.67% | -251.63% | -95.25% | -207.24% | 0.00% |
| EPS | -3.86 | -3.08 | -2.47 | -1.62 | -0.81 | -1.15 | -0.85 |
| EPS Diluted | -3.86 | -3.08 | -2.47 | -1.62 | -0.81 | -1.15 | -0.85 |
| Weighted Avg Shares Out | 113.15M | 80.63M | 72.81M | 66.60M | 59.00M | 36.47M | 36.47M |
| Weighted Avg Shares Out (Dil) | 113.15M | 80.63M | 72.81M | 66.60M | 59.00M | 36.47M | 36.47M |
Source: https://incomestatements.info
Category: Stock Reports